Available from PepTek
The SURPASS clinical trial program examined tirzepatide's dual GIP/GLP-1 receptor agonism across six large-scale trials, revealing significant findings in metabolic research models.
The SURPASS clinical trial program represents one of the most comprehensive investigations into a dual incretin receptor agonist conducted to date. Spanning six major phase 3 trials, the tirzepatide SURPASS trial research program systematically examined the pharmacological behavior of tirzepatide — a synthetic peptide that simultaneously engages both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors — across a range of metabolic and glycemic research contexts. This summary consolidates key findings from the SURPASS series for the benefit of researchers seeking a structured overview of the published data.
For researchers already familiar with single-receptor incretin agonists, tirzepatide’s dual-agonist mechanism marks a meaningful departure from prior investigational frameworks. A detailed overview of tirzepatide’s receptor pharmacology, binding kinetics, and molecular structure is available in PepTek’s companion article, Tirzepatide: GLP-1/GIP Dual Agonist Research Profile.
The SURPASS program (SURPASS-1 through SURPASS-6, plus SURPASS-CVOT) was designed to evaluate tirzepatide across a spectrum of comparator conditions. Each sub-trial enrolled distinct subject populations and employed varying active or placebo comparators, allowing researchers to assess tirzepatide’s behavior in isolation and relative to other agents. The trials collectively enrolled tens of thousands of participants over multi-year observation windows, generating a substantial longitudinal dataset.
SURPASS-1 examined tirzepatide as a standalone intervention in subjects with type 2 diabetes not currently receiving pharmacological intervention. Published findings from Rosenstock et al. demonstrated that subjects receiving tirzepatide at 5 mg, 10 mg, and 15 mg weekly doses achieved statistically significant reductions in HbA1c from baseline compared to placebo at 40 weeks [Rosenstock et al., 2021]. Researchers noted dose-dependent HbA1c reductions of approximately 1.87%, 1.89%, and 2.07% across the three dose cohorts, respectively. The study also documented significant changes in body weight measurements across all active arms.
Perhaps the most widely cited component of the tirzepatide SURPASS trial research program, SURPASS-2 placed tirzepatide in direct comparison with semaglutide 1 mg in subjects with type 2 diabetes. Frías et al. reported that tirzepatide at all three studied doses demonstrated superior HbA1c reduction relative to semaglutide 1 mg at 40 weeks [Frías et al., 2021]. The 15 mg tirzepatide cohort showed a mean HbA1c reduction of 2.46% from baseline, compared to 1.86% in the semaglutide group. Researchers studying GLP-1 receptor agonism may find it useful to reference PepTek’s article on Semaglutide: GLP-1 Receptor Agonist Research and Mechanism of Action to contextualize these comparative findings within the broader incretin research landscape.
SURPASS-3 evaluated tirzepatide against basal insulin degludec over 52 weeks in subjects already receiving metformin. Ludvik et al. reported that all tirzepatide dose groups demonstrated non-inferior and ultimately superior HbA1c reductions compared to titrated insulin degludec [Ludvik et al., 2021]. Notably, the tirzepatide cohorts showed mean body weight reductions ranging from approximately 7.5 kg to 12.9 kg, while the insulin degludec group experienced a mean weight increase of approximately 2.3 kg. Researchers noted that the divergence in body weight trajectories between the two treatment arms represents a potentially important distinction in the mechanism of action between the dual agonist and basal insulin.
SURPASS-4 enrolled subjects with type 2 diabetes and established cardiovascular risk factors, comparing tirzepatide to insulin glargine over 52 weeks. Del Prato et al. documented that tirzepatide produced significantly greater HbA1c reductions than glargine at all dose levels, with a mean reduction of up to 2.58% in the highest tirzepatide cohort [Del Prato et al., 2021]. Researchers also examined markers associated with hepatic fat, lipid profiles, and blood pressure across observation windows. The cardiovascular-risk-enriched design of SURPASS-4 distinguishes it from other trials in the series and has made it a reference point for researchers studying metabolic-cardiovascular intersections. This mechanistic interest in cellular energy metabolism parallels research conducted on coenzymes involved in redox signaling, such as those reviewed in NAD+: Coenzyme Research Profile and Cellular Metabolism Studies.
SURPASS-5 assessed tirzepatide as an adjunctive compound alongside insulin glargine and metformin. Published data demonstrated consistent HbA1c reduction and body weight outcomes across tirzepatide dose groups when added to existing insulin-based regimens, reinforcing the observations made in earlier SURPASS trials.
While technically outside the SURPASS designation, the SURMOUNT-1 trial extended tirzepatide SURPASS trial research themes into a non-diabetic obesity context. Jastreboff et al. reported that subjects with obesity receiving 15 mg tirzepatide weekly achieved a mean body weight reduction of approximately 20.9% from baseline over 72 weeks, compared to 3.1% in the placebo group. This trial was particularly significant because it enrolled subjects without type 2 diabetes, isolating tirzepatide’s effects on adiposity from its glycemic activity. The findings have stimulated additional mechanistic research into how dual GIP/GLP-1 receptor co-activation influences adipocyte biology and energy expenditure signaling pathways.
Researchers studying the broader landscape of peptide-based hormonal modulators may also find relevance in related investigations such as PepTek’s overview of Retatrutide: Triple GIP/GLP-1/Glucagon Agonist Research Overview, which extends this dual-agonist framework into a triple-receptor model, and the Tesamorelin: GHRH Analogue Research Profile and Studied Effects article for comparison with growth hormone-releasing hormone analogues studied in metabolic contexts.
Across the SURPASS series, gastrointestinal adverse events — including nausea, vomiting, and diarrhea — represented the most frequently documented tolerability signals, consistent with the class effects observed with GLP-1 receptor agonists. These events were predominantly mild to moderate in intensity and were most common during initial dose escalation phases. Hypoglycemia events were rare in monotherapy contexts but increased in trials where tirzepatide was combined with insulin, as expected from the pharmacodynamic overlap between dual incretin agonism and exogenous insulin administration.
Researchers have noted that the tolerability profile observed across tirzepatide SURPASS trial research data generally aligns with that of single-receptor GLP-1 agonists, though the dual-receptor engagement introduces pharmacological considerations that warrant continued mechanistic investigation in preclinical and in vitro settings.
The tirzepatide SURPASS trial research program provides a substantial body of published clinical data that researchers can reference when designing in vitro studies, animal model experiments, or mechanistic investigations involving GIP and GLP-1 receptor co-activation. The molecular architecture of tirzepatide — a single 39-amino acid peptide engineered to act at two incretin receptors — continues to serve as a model for next-generation dual and multi-agonist peptide research.
Investigators interested in the broader context of synthetic peptide pharmacology, including receptor selectivity, signaling cascades, and peptide stability, are encouraged to explore additional research profiles within the PepTek research library to build comparative mechanistic frameworks.
Research Use Disclaimer: All information presented in this article is intended strictly for research and educational purposes. Tirzepatide and all compounds discussed herein are research chemicals intended for use in authorized laboratory and preclinical research settings only. This content does not constitute medical advice, clinical guidance, or therapeutic recommendations of any kind. No information in this article should be interpreted as promoting, endorsing, or guiding the use of tirzepatide or any related compound in humans or animals. PepTek supplies compounds exclusively for legitimate scientific research purposes.
